April 10, 2020

BioTissue Announces First Annual National Mechanical Dry Eye Day

Day to bring awareness to Mechanical Dry Eye (MDE), one of the most overlooked and often misdiagnosed age-related eye conditions

Miami, FL – April 10, 2020 – BioTissue, Inc., a TissueTech, Inc. company and leader in the clinical application of cryopreserved amniotic membrane products for ocular surface disease and disorders, has announced the first-ever National Mechanical Dry Eye Day. Recognized by the National Day Archives as an official holiday on the National Day Registry™, National Mechanical Dry Eye Day will be celebrated annually on May 19.

“Mechanical Dry Eye, or MDE, is an age-related disorder, often found in individuals over 60. This condition is also known as Conjunctivochalsis and can be misdiagnosed or overlooked because the symptoms are similar to other types of dry eye disease. Normal eyes have a space between the eyeball and the lower eyelid that hold a reservoir of tears. Tears from this reservoir are spread over the eye during the blinking process, ” said Scheffer C.G. Tseng, MD, PhD, Chief Technology Officer at TissueTech. “In MDE, excess folds of loose and wrinkled conjunctiva can block this tear reservoir, preventing tear retention, tear spreading, and causing dry eyes. Symptoms of MDE can include dryness, eye pain, redness, blurry vision, or excessive watering of the eye. Blinking makes these symptoms worse.”

To celebrate National Mechanical Dry Eye Day, BioTissue will kick off its social media initiative, #MDEMondays, on May 4, featuring videos of leading ophthalmologists sharing their experience diagnosing and treating their patients with Mechanical Dry Eye. The #MDEMonday videos can be viewed on BioTissue’s Facebook,LinkedIn, and Twitter pages. BioTissue will also showcase its www.DiscoverMDE.com website intended to help ophthalmologists and optometrists learn more about how MDE is different from conventional dry eye. It features information on an outpatient procedure known as Reservoir Restoration using BioTissue’s AmnioGraft®, a cryopreserved biologic ocular transplantation graft. Patient education materials, including a new animation and patient brochures, are also available on the website for healthcare professionals to share with patients they feel could be suffering from Mechanical Dry Eye.

TissueTech, and its wholly-owned subsidiaries BioTissue and Amniox, are committed to addressing unmet patient needs. As such, the organization maintains a product portfolio of amniotic membrane and umbilical cord birth tissue products to help manage ocular surface diseases, complex surgical wounds, and musculoskeletal disorders.

About BioTissue, Inc.

BioTissue, Inc., a TissueTech, Inc. company, is the market leader in the clinical application of cryopreserved amniotic membrane-based products for the treatment of diseases and disorders of the ocular surface. Established in 1997, BioTissue® serves an unmet need for better surgical and therapeutic alternatives for helping eye care professionals manage ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis, pterygium, and dry eye. Connect with BioTissue on our Website, Facebook,LinkedIn, and Twitter.

About TissueTech, Inc.

TissueTech, Inc., the parent company of Amniox Medical, Inc. and BioTissue, Inc., pioneered the development and clinical application of human birth tissue-based products. Founded in 1997, BioTissue markets products for the ophthalmology and optometry markets; and Amniox markets products for use in the musculoskeletal and wound care markets. Clinicians have performed more than 500,000 human implants with the company’s products and published more than 360 peer-reviewed studies supporting its products and platform technology. The company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA to act as an anti-inflammatory anti-scarring and anti-angiogenic agent. Learn more at https://biotissue.com/.

Related Content